Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

Following its $20 billion asset swap with GlaxoSmithKline last year, Novartis is to split its pharmaceutical division in two, creating two business units, with the former single business unit's ...

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

Analyst Etzer Darout of BMO Capital maintained a Hold rating on Novartis (NVS – Research Report), retaining the price target of $118.00.

Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new drugs like gene therapy Zolgensma gathered pace. Correcting for currency ...

Aug 24 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab said on Saturday it had received a binding offer from Germany's Siemens Healthineers (SHLG.DE), opens new tab to acquire its ...

Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...

Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Monday updated analysis from the pivotal Phase III ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

Novartis NVS said it received accelerated ... This reduction in protein compared with a 9% drop in the placebo arm, the Swiss pharmaceutical company said Wednesday.